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Abstract 
153Sm-EDTMP is a radiopharmaceutical composed of EDTMP (ethylenediamine-
tetramethylenephosphonate) and Samarium-153 [1]. 153Sm-EDTMP has an affinity for 
skeletal tissue and concentrates in areas with increased bone turnover; thus, it is 
successfully used in relieving pain related to diffuse bone metastases [1]. The 
manufacturing process of 153Sm-EDTMP leads to contamination with 154Eu (Europium-
154) [2]. A previous study only alluded to the retention of 154Eu in the bones after 
receiving treatment with 153Sm-EDTMP [2]. Activation of the alarm at security 
checkpoints after 153Sm-EDTMP therapy has not been previously reported. Two out of 15 
patients who received 153Sm-EDTMP at Roger Maris Cancer Center (Fargo, N. Dak., USA) 
activated the radiation activity sensors while passing through checkpoints; one at a US 
airport and the other while crossing theAmerican-Canadian border. We assume that the 
154Eu which remained in the patients’ bones activated the sensors.  
Methods: In order to investigate this hypothesis, we obtained the consent from 3 of our 
15 patients who received 153Sm-EDTMP within the previous 4 months to 2 years, 
including the patient who had activated the radiation alarm at the airport. The patients 
were scanned with a handheld detector and a gamma camera for energies from 511 keV 
to 1.3 MeV.  
Results: All three patients exhibited identical spectral images, and further analysis 
showed that the observed spectra are the result of 154Eu emissions.  
Conclusion: Depending on the detection thresholds and windows used by local and 
federal authorities, the remaining activity of 154Eu retained in patients who received 
153Sm-EDTMP could be sufficient enough to increase the count rates above background  
Case Rep Oncol 2009;2:157–161 
DOI: 10.1159/000235809 
Published online: August 28, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
158
levels and activate the sensors. At Roger Maris Cancer Center, patients are now informed 
of the potential consequences of 153Sm-EDTMP therapy prior to initiating treatment. In 
addition, patients treated with 153Sm-EDTMP at Roger Maris Cancer Center receive 
laminated cards stating the date and the dose of treatment, as well as a statement that 
the holder may activate the alarm at the security checkpoints. 
 
Intoduction 
Several modalities are applied for palliative therapies for metastatic bone pain, 
including the use of opioid analgesics and systemic chemotherapy. However, most of the 
patients with hormone-resistant prostate cancer are elderly and frail and do not tolerate 
the chemotherapy well. External beam radiotherapy provides excellent palliation for focal 
painful bone lesions; however, in patients with systemic disease, repeated courses may be 
required for palliation [3]. 
Another treatment option for the pain secondary to metastatic bone disease is the 
administration of bone-seeking radiopharmaceutical agents. These include phosphorus-
32, strontium-89 and samarium-153 [4]. Phosphorus-32 and strontium-89 have been 
studied extensively. Both of these agents are effective in relieving the pain from 
osteoblastic metastases, but both have properties that limit their utility. The long physical 
half-life of strontium-89 (50.5 days) results in a slow delivery of the dose of radiation as 
well as a prolonged and variable suppression of the hematopoietic elements [5]. However, 
the physical half-life of 
153Sm is 46.3 h [6], and its excretion is completed 6 h after 
administration [7]. The 
153Sm-EDTMP complex localizes to bone with greater avidity for 
areas of bone turnover [8–10]. The areas of metastatic involvement can accumulate 
significant amounts of 
153Sm-EDTMP compared to surrounding normal bone [7, 11]. 
This form of treatment targets multiple osteoblastic sites simultaneously, both 
symptomatic and asymptomatic. In the latter case, it may delay the onset of the symptoms 
of such sites for several months and, therefore, delay the need for treatment [11]. Usually, 
patients can benefit from a single injection, with pain relief beginning within the first few 
weeks and often lasting for several months. Although the pain relief usually is life-long, 
patients can be treated at intervals varying from as short as 8–12 weeks to as long as 1 
year, if needed [11]. The only significant toxic effect associated with 
153Sm-EDTMP is 
mild transient myelosuppression [1, 8–10, 12]. 
The manufacturing process of 
153Sm-EDTMP leads to contamination with 
154Eu 
(Europium-154) which has a physical half-life of 8.5 years [2]. A previous study alluded to 
the retention of 
154Eu in the bones after receiving treatment with 
153Sm-EDTMP [2]. 
Method and Materials 
Two out of 15 patients who received 
153Sm-EDTMP at Roger Maris Cancer Center activated the 
radiation sensors while passing through check-points; one at a US airport and the other while crossing 
the American-Canadian border. We assume that the 
154Eu which remained in the patients’ bones 
activated the sensors. In order to investigate this hypothesis we obtained the consent from 3 of our 15 
patients who received 
153Sm-EDTMP within the previous 4 months to 2 years, including the patient who 
had activated the radiation alarm at the airport. 
The criteria used to select those 3 patients included: they had a 
153Sm-EDTMP dose between 75 mCi 
and 107 mCi 4 months to 2 years prior to the study and live close to our facility for their own 
convenience.  
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Portable handheld meters were used to determine if an increased exposure or count rate could be 
measured in these patients. The sensitivity of a Geiger-Müller detector (Ludlum Measurements Inc., 
Sweetwater, Tex., USA) was not sufficient to detect an exposure increase beyond background levels; 
however, a small increase was observed when a scintillation detector (Ludlum Measurements Inc.) 
indicated a count rate up to twice the background level at a patient’s surface. 
To investigate the emission spectra emanating from these patients, a SPECT gamma camera was 
calibrated with the collimators removed to display a graphical readout of counts versus energy. The 
camera was calibrated with high energy sources between 511 keV and 1.3 MeV to improve its accuracy. 
Since the official energy range of the scanner was from 50–511 keV, additional offline correction factors 
obtained during the calibration procedure were used to improve the accuracy of our measurements. 
Prior to each scan, the test patients were removed from the area and a background measurement was 
obtained. With the crystal approximately 30 cm from the patient’s surface, the scanner was run in a 
cumulative mode until a predetermined count value was reached. 
Results 
The 5 observed peak energies were extracted during the analysis of the graphical 
printouts. All 3 patients exhibited identical spectral images. Fig. 1 shows the observed 
peaks prior to the offline corrections. Applying the offline correction factors to the peaks 
revealed the following energies with an uncertainty of ±7.5 keV: 1,277, 1,003, 877, 729, 
and 595 keV. The most probable emissions between 511 keV and 1.3 MeV for 
154Eu are 
1,274.4, 1,004.7, 996.3, 873.2, 723.3, and 591.8 keV [13–15]. The agreement of the 
measured values to within 1% of the expected energies supports our theory that the 
increased count rates and observed spectra are the result of 
154Eu emissions. 
An additional scan was performed on 1 patient with the scan window set to count the 
most probable 
154Eu emission, a 123 keV gamma ray [14]. After selecting the appropriate 
calibration settings the counting window was centered on 123 keV with a 15% energy 
window. The measured counts increased by a factor of 9 from 0.1 to 0.9 kcts/s with a 
visible peak at 123 keV. With this lower energy window setting we observed increased 
count rates on the posterior side of all patients. We have attributed this observation to the 
accumulation of 
154Eu in the vertebral bodies, which results in less attenuating tissue 
between the source of emissions and the detector when counting on the posterior side. 
Conclusion 
The low amounts of residual 
154Eu remaining in patients’ bones after receiving 
153Sm-
EDTMP treatment cannot be reliably detected using standard handheld detectors, with 
the exception of scintillation detectors placed very close to the patient. Since many of 
154Eu’s emissions are in the high keV range, these types of detectors do not have the 
necessary efficiency to directly detect the majority of emitted photons. The increased 
efficiency afforded by larger stationary detectors used by local and federal authorities 
could easily detect an increase in counts beyond background levels over a wide spectrum 
of energies. 
The potential activation of the sensors at checkpoints should not be a limitation to the 
use of 
153Sm-EDTMP as previous studies have shown the additional radiation burden is 
negligible [16]. 
Authorized users of 
153Sm-EDTMP should be aware of the additional implication 
associated with the presence of 
154Eu. Physicians should use their discretion in informing  
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patients about the residual amount of 
154Eu and the potential activation of the detectors at 
the Homeland security checkpoints. 
Roger Maris Cancer Center has started providing the patients who have received 
153Sm-EDTMP with laminated cards stating the date and the dose of treatment, as well as 
a statement that the holder may activate the alarm at the security checkpoint. We strongly 
recommend other treatment centers to also provide their patients with the laminated 
cards to assure the patients safety. 
 
 
 
 
 
Fig. 1. A graphical printout of counts versus energies without offline corrections applied (obtained 
from a patient 2 years after injection by a gamma camera without collimators). Energies above 855 keV 
are by a factor of 10 greater than indicated on the graph, as verified with calibration sources. 
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